Biodexa Sets 1-for-8 ADS Reverse Split Effective October 26
Summary
Biodexa announced a mandatory 1-for-8 reverse split of its ADSs effective October 26, 2026, changing the ADS-to-ordinary-share ratio from 1:50 to 1:400. The move aims to boost the ADS price amid a going-concern warning and dwindling cash reserves.
Key Events · Corporate Governance and Compliance · BDRX
-
1-for-8 ADS Reverse Split
Mandatory exchange of 8 old ADSs for 1 new ADS, effective on or about October 26, 2026. New CUSIP 59564R864 replaces old CUSIP 59564R872.
-
ADS Ratio Change
Each new ADS will represent 400 ordinary shares, up from 50 ordinary shares per ADS. Ordinary shares are unaffected.
-
NASDAQ Compliance Motivation
The reverse split is intended to raise the ADS price above NASDAQ's minimum bid requirement, following a going-concern warning and £3.23 million cash balance at June 30, 2026.
-
Depositary Arrangements
JPMorgan Chase Bank, N.A. will contact ADS holders to arrange the mandatory exchange. No fractional ADSs will be allocated; aggregate fractions will be sold and net proceeds distributed.
Analysis · BDRX · Life Sciences
Biodexa is implementing a 1-for-8 reverse split of its American Depositary Shares, effective on or about October 26, 2026. Each new ADS will represent 400 ordinary shares, up from 50, and holders must exchange 8 old ADSs for 1 new ADS. The ordinary shares themselves are unaffected. This follows the shareholder-approved 1-for-10,000 reverse split of ordinary shares in July and comes amid a going-concern warning and a cash balance of only £3.23 million at June 30, 2026. The ADS ratio change is designed to lift the ADS price above NASDAQ's minimum bid requirement, but it does not change the company's underlying financial distress.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 31.5% of the 1750 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $360.4K. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.